The Efficacy and Immunomodulatory Effects of Ulinastatin and Thymosin α 1 for Sepsis: A Systematic Review and Meta-Analysis

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Wang, Feng Yun ^a   Fang, Bin ^a   Qiang, Xin Hua ^a   Yu, Tie Ou ^a   Zhong, Jia Rong ^a   Cao, Jun ^a   Zhou, Li Xin ^a  

^a THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

Author keywords

[No Author keywords available]

Indexed keywords

THYMOSIN ALPHA1; ULINASTATIN; GLYCOPROTEIN; IMMUNOLOGIC FACTOR; THYMOSIN;

APACHE; ARTIFICIAL VENTILATION; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; DRUG EFFICACY; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; INTENSIVE CARE UNIT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SURVIVAL RATE; SYSTEMATIC REVIEW; TIME; ADULT; AGED; ANALOGS AND DERIVATIVES; CAUSALITY; COMORBIDITY; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; MORTALITY; PREVALENCE; RESPIRATORY INSUFFICIENCY; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CAUSALITY; COMORBIDITY; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY; RISK FACTORS; SEPSIS; SURVIVAL RATE; THYMOSIN; TREATMENT OUTCOME;

EID: 84975222172     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/9508493     Document Type: Review

References (30)

1. R. C. Bone, R. A. Balk, F. B. Cerra et al., "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis, " Chest, vol. 101, no. 6, pp. 1644-1655, 1992.
2. R. P. Dellinger, M. M. Levy, A. Rhodes et al., "Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012, " Critical Care Medicine, vol. 41, no. 2, pp. 580-637, 2013.
3. R. S. Hotchkiss and I. E. Karl, "The pathophysiology and treatment of sepsis, "The New England Journal of Medicine, vol. 348, no. 2, pp. 138-150, 2003.
4. M. M. Levy, A. Artigas, G. S. Phillips et al., "Outcomes of the surviving sepsis campaign in intensive care units in the USA and Europe: a prospective cohort study, " The Lancet Infectious Diseases, vol. 12, no. 12, pp. 919-924, 2012.
5. M. Haniuda, M. Morimoto, A. Sugenoya, and F. Lida, "Suppressive effect of ulinastatin on plasma fibronectin depression after cardiac surgery, " The Annals of Thoracic Surgery, vol. 45, no. 2, pp. 171-173, 1988.
6. H. Yang, Y. Mao, X. Lu et al., "The effects of urinary trypsin inhibitor on liver function and inflammatory factors in patients undergoing hepatectomy: a prospective, randomized, controlled clinical study, "The American Journal of Surgery, vol. 202, no. 2, pp. 151-157, 2011.
7. T. Tsujino, Y. Komatsu, H. Isayama et al., "Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial, " Clinical Gastroenterology and Hepatology, vol. 3, no. 4, pp. 376-383, 2005.
8. J. Y. Park, T. J. Jeon, M. W. Hwang et al., "Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications: a prospective, randomized trial, " Pancreatology, vol. 14, no. 4, pp. 263-267, 2014.
9. R. Uchino, H. Isayama, T. Tsujino et al., "RESULTS of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial, " Gastrointestinal Endoscopy, vol. 78, no. 6, pp. 842-850, 2013.
10. S. Itaba, K. Nakamura, A. Aso et al., "Prospective, randomized, double-blind, placebo-controlled trial of ulinastatin for prevention of hyperenzymemia after double balloon endoscopy via the antegrade approach, " Digestive Endoscopy, vol. 25, no. 4, pp. 421-427, 2013.
11. P. Abraham, J. Rodriques, N. Moulick et al., "Efficacy and safety of intravenous ulinastatin versus placebo along with standard supportive care in subjects with mild or severe acute pancreatitis, " The Journal of the Association of Physicians of India, vol. 61, no. 8, pp. 535-538, 2013.
12. J. E. McClure, N. Lameris, D. W. Wara, and A. L. Goldstein, "Immunochemical studies on thymosin: radioimmunoassay of thymosin 1, " The Journal of Immunology, vol. 128, no. 1, pp. 368-375, 1982.
13. J. Wu, L. Zhou, J. Liu et al., "The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial, " Critical Care, vol. 17, no. 1, article R8, 2013.
14. Y. Zhang, H. Chen, Y.-M. Li et al., "Thymosin 1-and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria, " Journal of Infectious Diseases, vol. 198, no. 5, pp. 723-730, 2008.
15. L. Yumin, C. Hao, L. Xun et al., "A new immunomodulatory therapy for severe sepsis: ulinastatin plus thymosin 1, " Journal of Intensive Care Medicine, vol. 24, no. 1, pp. 47-53, 2009.
16. H. Chen, M.-Y. He, and Y.-M. Li, "Treatment of patients with severe sepsis using ulinastatin and thymosin 1: a prospective, randomized, controlled pilot study, " Chinese Medical Journal, vol. 122, no. 8, pp. 883-888, 2009.
17. S.-W. Huang, J. Chen, B. Ouyang, C.-H. Yang, M.-Y. Chen, and X.-D. Guan, "Immunotherapy improves immune homeostasis and increases survival rate of septic patients, " Chinese Journal of Traumatology, vol. 12, no. 6, pp. 344-349, 2009.
18. H.-Y. Lin, "Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with ulinastatin and maipuxin, " Zhonghua Yi Xue Za Zhi, vol. 87, no. 7, pp. 451-457, 2007.
19. L. Su, F. S. Meng, Y. Q. Tang et al., "Clinical effects of ulinastatin and thymosin alpha1 on immune-modulation in septic patients, "Chinese Critical CareMedicine, vol. 21, no. 3, pp. 147-150, 2009.
20. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, "Measuring inconsistency in meta-analyses, " British Medical Journal, vol. 327, no. 7414, pp. 557-560, 2003.
21. R. C. Bone, R. A. Balk, F. B. Cerra et al., "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992, " Chest, vol. 136, no. 5, supplement, p. e28, 2009.
22. R. P. Dellinger, J. M. Carlet, H. Masur et al., "Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock, " Critical CareMedicine, vol. 32, no. 3, pp. 858-873, 2004.
23. Y. Zhang, Z. Zeng, Y. Cao, X. Du, and Z. Wan, "Effect of urinary protease inhibitor (ulinastatin) on cardiopulmonary bypass: a meta-analysis for China and Japan, " PLoS ONE, vol. 9, no. 12, Article ID e113973, 2014.
24. S.-Y. Oh, J. C. Kim, Y. S. Choi, W. K. Lee, Y.-K. Lee, and Y. L. Kwak, "Effects of ulinastatin treatment onmyocardial and renal injury in patients undergoing aortic valve replacement with cardiopulmonary bypass, " Korean Journal of Anesthesiology, vol. 62, no. 2, pp. 148-153, 2012.
25. J. E. Song, W. S. Kang, D. K. Kim et al., "The effect of ulinastatin on postoperative blood loss in patients undergoing open heart surgery with cardiopulmonary bypass, " The Journal of InternationalMedical Research, vol. 39, no. 4, pp. 1201-1210, 2011.
26. L. Hui, F. Shen, H. Chang, X. Li, G. Gao, and J. Ma, "Effects of ulinastatin on cerebral oxygen metabolism and CRP levels in patients with severe traumatic brain injury, " Experimental and Therapeutic Medicine, vol. 7, no. 6, pp. 1683-1686, 2014.
27. H. M. Wu, J.-L. Tang, L. Cao, Z. H. Sha, and Y. Li, "Interventions for preventing infection in nephrotic syndrome, " Cochrane Database of Systematic Reviews, vol. 4, Article ID CD003964, 2012.
28. X. Wang, W. Li, C. Niu, L. Pan, N. Li, and J. Li, "Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a doubleblind randomized control study, " Inflammation, vol. 34, no. 3, pp. 198-202, 2011.
29. R.-N. Chien, Y.-F. Liaw, T.-C. Chen, C.-T. Yeh, and I.-S. Sheen, "Efficacy ofThymosin 1 in patients with chronic hepatitis B: a randomized, controlled trial, " Hepatology, vol. 27, no. 5, pp. 1383-1387, 1998.
30. J.-H. Ding, L.-L. Wang, Z. Chen et al., "The role of T1 on the infective patients after hematopoietic stemcell transplantation, " International Journal of Hematology, vol. 97, no. 2, pp. 280-283, 2013.